KINTARA THERAPEUTICS, INC.

Medtech · Acquired

REM-001, a photodynamic therapy combining a photosensitive drug and specialized laser system for treating cutaneous metastatic breast cancer

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$2M
Federal grants
$2M
2 awards · 2023–2024
Rank in peer group#46 of 477
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20232024FEDERAL ↑EQUITY ↓Cumulative $2M$1.3M$745K
20232024FEDERAL ↑EQUITY ↓Cumulative $2M$1.3M$745K

Latest events

  • Federal grantHealth and Human S · Phase II · An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)$745K
  • Federal grantHealth and Human S · Phase II · An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)$1.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 477 peers

Line = median

Medtech · Device

  • Federal grants#46 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Dennis BrownResearcherExecutive OfficerLinked by $2M in grants as PI
  • John LiatosExecutive Officer, DirectorNamed in SEC Form D filings
  • Keith MurphyDirectorNamed in SEC Form D filings
  • Laura JohnsonDirectorNamed in SEC Form D filings
  • Robert HoffmanDirectorNamed in SEC Form D filings
  • Robert TothDirectorNamed in SEC Form D filings
Show all 9 people
  • Saiid ZarrabianExecutive Officer, DirectorNamed in SEC Form D filings
  • Scott PraillExecutive OfficerNamed in SEC Form D filings
  • Steven RychnovskyExecutive OfficerNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • CELL IDX, INC.Similar federal contract value in Medtech · null in contracts
  • ENABLE INJECTIONS, INCSimilar federal contract value in Medtech · null in contracts
  • NEUROCOG TRIALSSimilar federal contract value in Medtech · null in contracts
  • PROTEGO BIOPHARMA, INC.Similar federal contract value in Medtech · null in contracts
  • BOSE CORPORATIONSimilar federal contract value in Medtech · null in contracts
  • T-NEURO, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .